Therapy guide · medical education
Keratosis pilaris (chicken skin): the full therapy pathway
What actually moves the bumps, why the redness around them mostly does not, and the maintenance schedule that separates a result that holds from one that lasts three weeks.
Before anything else
Not everyone should start at the bottom of this pathway. These presentations are reasons to
see a clinician without waiting out an over-the-counter trial first.
- Pitting, honeycomb scarring, or skin that looks thinned where bumps have been See a dermatologist soon
Scarring separates the ordinary form from a group of variants that destroy the follicle rather than merely plugging it. What has already been lost cannot be restored, and the only realistic goal is halting progression — which makes this the one presentation here where the appointment is worth arranging now rather than after a trial of creams.
- Loss of eyebrow hair, eyelashes, or patchy thinning of the scalp See a dermatologist soon
Follicular destruction reaching the eyebrows or scalp points to the scarring variants, in which hair loss is permanent once the follicle has gone. Published series describe scalp involvement appearing in the teenage years after childhood-onset skin disease, so the window is real and it closes.
- Light sensitivity, gritty or painful eyes, or a change in vision alongside the skin condition Seek care quickly
Eye abnormalities including photophobia, corneal deposits and early cataracts have been reported alongside the scarring variants, and an eye examination is part of assessing them. Anything painful or affecting sight is assessed the same day rather than at a routine review.
- A field of follicular bumps appearing for the first time in adulthood Worth a clinician visit
This condition ordinarily begins in childhood or adolescence. A similar-looking eruption arriving in an adult over weeks is a different question — drug-induced follicular eruptions are described with certain targeted cancer therapies, and other causes exist. New adult onset is worth a diagnosis rather than a keratolytic.
- Bumps that have become painful, hot, or are draining See a dermatologist soon
Plugged follicles are neither tender nor productive. Pain, warmth or discharge suggests infection of the follicle rather than obstruction of it, and that is treated differently — sometimes with an antibiotic, and never with a stronger exfoliant.
- Skin that has become raw, weeping, or paler in patches after prolonged treatment Worth a clinician visit
Two self-inflicted problems account for most of this. Persistent mechanical scrubbing inflames the perifollicular skin and leaves it worse than it started. Regular use of a topical corticosteroid on the area thins it, which is why guidance permits only a few days at a time and warns against routine use.
Which column does this sit in?
Three questions do most of the sorting: whether anything is being permanently lost, whether the complaint is the roughness or the colour, and whether it itches. Answers stay in this browser and are never sent anywhere.
Seven questions, none about identity and none required. The result names a column and a position on it, then filters the page to that column — the others stay one button away.
One thing to be clear about. This places a description on a map; it does not say what anything is. A few conditions produce similar-looking bumps and one group of variants looks ordinary until it starts leaving marks, so a result here is a starting point for a conversation rather than a replacement for one.
What this looks like
There is no severity scale in general use, and the useful description is not how bad it is but which of its two components dominates. Every case is some mixture of plugged follicles and the redness around them, and those two respond so differently to treatment that describing a case without separating them makes the result unreadable.
The everyday form
Fine rough papules on the outer upper arms or thighs, with little colour, in a child or adolescent.
What it looks like: Skin that feels like fine sandpaper and looks unremarkable at arm's length. Mild forms in this age group are common enough to be regarded as a normal variant rather than a disease, which is a reasonable position and not a dismissal of anyone bothered by it.
Roughness dominant
Numerous firm plugs across a wide area, where the complaint is how it feels and how it catches the light rather than its colour.
What it looks like: Dense stippling over the backs of the arms, thighs or buttocks, sometimes extending to the forearms and upper back. This is the presentation with the most to gain from treatment, because roughness is the half that measurably answers.
Redness dominant
Marked erythema around the follicles, sometimes across a wide area of cheek, arm or thigh, with the plugs themselves a secondary feature.
What it looks like: A red or flushed field with follicular prominence in it, most often on the outer cheeks and the upper arms and legs, typically starting in early childhood. Described as a variant in its own right, and the one where published treatment results are consistently poorest.
Followed by scarring or hair loss
Bumps that leave something behind — small pitted depressions, honeycomb scarring, or loss of hair in the affected skin.
What it looks like: Most often on the cheeks and pre-auricular skin, or in the eyebrows and scalp with thinning where the follicles have been destroyed. This group is uncommon, behaves differently, and is the only presentation here where delay costs something that cannot be recovered.
Three things that change the plan regardless of severity
Eczema, very dry skin, or a family history of both
The association is real and it is genetic rather than coincidental: in a study of five hundred people with atopic dermatitis, keratosis pilaris tracked strongly with palmar hyperlinearity and with a filaggrin loss-of-function variant, both markers of the same barrier defect. Practically, it means the emollient is not an optional comfort layer here — it is treating the substrate the plugs are forming in, and the keratolytic works better on skin that is already being kept hydrated.
Winter
Four in five people in the only natural-history survey reported a seasonal swing, and among those it split almost evenly between improving in summer and worsening in winter. That has two consequences worth knowing in advance: a treatment started in October is fighting the season as well as the condition, and a result judged in July may be flattered by it. Comparing like months is what keeps the assessment honest.
Diabetes, higher body weight, or signs of androgen excess
It appeared in twelve per cent of young people with type 1 diabetes against one and a half per cent of matched controls in one study, and it is described alongside higher body mass index and androgen excess. None of that changes the topical plan, and it does change what an appointment is for: extensive or unusually abrupt disease is one of the few situations in which a clinician may look for something underneath rather than simply treating the surface.
Richer skin tones
Two things differ. The redness reads as a darker or duskier tone rather than pink and is easily missed, so the colour component is under-recognised. And the marks the plugs leave behind are more likely to be brown than red and to last longer — which is also why the energy-based options at the top of these ladders carry a real pigment-change risk here, and why the practitioner's experience with the skin tone in front of them matters more than the device.
Pregnant, breastfeeding, or planning to be
The ladders shorten from the top down. Topical retinoids and oral isotretinoin come off entirely, elective laser is deferred rather than forbidden, and what remains is the whole non-prescription tier, which is where most of the benefit sits anyway. It is also worth knowing that this condition has been described as arising or worsening in pregnancy, so a flare then is not evidence that something was done wrong.
What else it could be
- Folliculitis — Tender pus-topped spots that appear in crops and clear over days. This condition is neither tender nor episodic — the same bumps are there next month, and the month after.
- Follicular eczema — Itchy, ill-defined and variable, with the itch out of proportion to what is visible. It waxes and wanes; keratosis pilaris sits still.
- Acne on the trunk or arms — Blackheads, whiteheads and inflamed spots of differing sizes and ages. The plugs here are uniform, permanent and never come to a head.
- Ichthyosis vulgaris — Fine fish-scale dryness on the shins with deeply etched palm lines. It sits alongside this condition rather than instead of it — the two share a barrier defect and are frequently found together.
- Lichen spinulosus — Grouped spiny follicular papules in a discrete patch, rather than the diffuse field of plugs seen here. Uncommon, and worth a clinician's look because it is easily read as a stubborn patch of the ordinary thing.
- Drug-induced follicular eruptions — A field of follicular papules appearing over weeks in an adult who has never had them, particularly after starting a targeted cancer therapy. Sudden adult onset is the signal — this condition ordinarily starts in childhood.
The single most useful distinguishing feature is time. This condition is stable: the same follicles are plugged this month as last, it does not arrive in crops, and it does not resolve and return. Anything that comes and goes, hurts, or appears for the first time in adulthood deserves a second look, because none of those are how this behaves.
Why it happens
Keratosis pilaris is a plumbing fault in the hair follicle. Instead of shedding, keratin accumulates and plugs the top of the follicular canal, and each plugged follicle becomes a small firm bump with a ring of pink around it. It is inherited in a substantial share of cases, runs in families, and typically arrives in childhood on the outer upper arms and the fronts of the thighs, sometimes the buttocks and the outer cheeks. It is not an infection, not a hygiene problem, and not acne — which matters, because all three of those assumptions lead somewhere unhelpful.
Anyone with a permanent field of small rough bumps that feel like sandpaper and look worse in a photograph than in a mirror. It is also for the large group who have worked steadily up through gritty scrubs, dry brushes and stronger acids over several years, found the texture briefly better and the redness worse, and concluded the problem is that they have not yet found the right product.
Orientation, not diagnosis. This page is a map rather than a diagnosis. The ordinary form is recognisable enough that most people identify it correctly, but a few things look similar and are handled differently: folliculitis, which is tender and comes and goes; the follicular pattern eczema can take on dry limbs; and, where bumps are followed by pitting, scarring or hair loss, a group of rarer variants that need a clinician rather than a keratolytic.
No prescription needed for any of this The over-the-counter pathway
The over-the-counter tier here is genuinely first-line, which is unusual on this site, and it is also close to the whole story. Keratolytics — lactic acid, glycolic acid, urea and salicylic acid — are what primary-care guidance names and what the recent systematic reviews identify as the preferred topicals. The best single piece of evidence is a split-side randomised trial in which ten per cent lactic acid reduced lesions by about two-thirds over three months and five per cent salicylic acid by about half, with mild local irritation the only adverse effect. What sits above this tier is not stronger versions of the same idea; it is a different mechanism aimed at a different half of the problem, and for most people it is not necessary.
Appropriate for: Essentially every presentation, as the foundation, and the complete answer for most of the ordinary texture-led form. Nothing higher up these ladders removes the need for it — the resurfacing devices at the top of one column are judged against continued topical treatment, not instead of it, and the plugs return within months of everything stopping.
Five steps, and two of them are about what to stop rather than what to start. The order matters: the shower and the emollient come before the acid, because a keratolytic applied to stripped skin stings enough to end the attempt, and the last step is the one that decides whether any of it is still working next year.
The failure mode: escalating at the half that does not answer
This condition has two components and they behave completely differently. The plugs respond to keratolytics — measurably, in a controlled trial, by about two-thirds over three months. The ring of colour around each follicle largely does not: the one properly controlled laser trial that improved roughness left redness statistically untouched, and the largest published series of the red variant reported minimal or no improvement across essentially every topical available. So the escalation people actually perform — a stiffer brush, a grittier scrub, a stronger acid, applied harder — is aimed at the half that does not answer, using the method most likely to inflame it further. The plan that works is unimpressive by comparison: one mild keratolytic, twice daily for three weeks, then once or twice a week for as long as it matters.
Anchored to UK primary-care guidance and to the split-side and sham-controlled trials that separate the two components.
Four rules worth more than the choice of product
- Scrubbing harder is the one escalation that reliably backfires. Friction cannot reach a plug seated inside the follicle, and what it does reach is the perifollicular skin producing the redness — so the method feels productive while making the untreatable half worse.
- Three weeks tells whether it is tolerated; twelve weeks tells how much it does. The trial that produced the numbers ran for three months, and abandoning at week four is how a working treatment gets recorded as a failure.
- This is maintenance rather than a course. Once or twice weekly application continues indefinitely, because the plugs re-form over weeks to months after treatment stops — which is the condition doing what it does, not the product having stopped working.
- Compare like seasons. Four in five people report a seasonal swing and it usually runs worse in winter, so a result judged across December to June is measuring the calendar at least as much as the treatment.
Answer as you go and the chart tracks where you are. Nothing is sent anywhere.
- Day 1You are here
Put the scrub down and take a baseline
Stop the one thing that makes this worse, and create the only reference point that will still be meaningful in three months.
What this step involves
Morning
- Retire the brush, the mitt and the gritty scrub Dry brushes, exfoliating gloves, loofahs, pumice, sugar and salt polishes, and anything sold as buffing the bumps away. All of them, rather than a reduced frequency — the goal is skin that is not being irritated when the keratolytic arrives, and a weekly scrub is still a weekly setback.
- Photograph the area in daylight, close and from a distance Two shots of the same patch, taken by a window rather than under a bathroom light, with something in frame for scale. Roughness photographs badly and colour photographs unreliably, which is exactly why a fixed reference matters more here than a recollection.
Evening
- Decide which half is actually the complaint Roughness, colour, or itch. The three answer to different treatments and the ladders diverge on this question, so naming it now prevents twelve weeks spent measuring the wrong thing. Most people find the honest answer is roughness, and are surprised.
Why this step: Mechanical exfoliation is both the default instinct and the thing most likely to have been making the condition look worse. Removing it first means the treatment below is being judged on its own rather than against a background of friction, and it means the skin is calm enough to tolerate an acid when one is introduced.
What's normal: Texture often feels marginally rougher in the first fortnight without the scrubbing, because the surface smoothing that friction produced has gone and the actual treatment has not started yet. That is expected.
Ready for the next step?
Has the mechanical exfoliation stopped, and is there a dated baseline photograph?
Yes — scrub retired, photo taken: That is the reference point set. Go to step 2 ↓ Go to step 1 ↓
Not yet: Both are worth doing before anything is bought. A keratolytic introduced onto scrubbed skin is the version of this plan that gets abandoned in week two.
- Week 0–1You are here
Change the shower before changing the shelf
Stop stripping the skin the treatment has to work on, which costs nothing and makes everything after it more tolerable.
What this step involves
Morning
- Shorter, cooler showers and a non-soap wash Hot water and detergent washes remove the lipids the barrier is already short of, and this condition sits disproportionately in people carrying an inherited barrier defect. A non-foaming or cream wash used only where it is needed is the change; the affected limbs mostly do not need washing with anything. Browse all cleansers →
- Emollient onto damp skin, within a few minutes Applied while the skin is still damp it holds substantially more water than applied later to dry skin. Quantity is the variable that matters over an area covering both arms and both thighs, and the usual error is a tenth of what the job needs. Browse all moisturizers →
Evening
- The same emollient again, unfragranced Fragranced body lotion is the most common avoidable irritant in this routine and the hardest to spot, because it is rarely dramatic — it simply keeps the skin slightly reactive. A plain ointment or thick cream is what the comparative trial actually tested. Browse all moisturizers →
Why this step: In the one blinded trial to test it, a plain petrolatum-based ointment performed comparably to a prescription anti-inflammatory. That result is usually filed as a curiosity and it is better read as a finding: the barrier underneath is part of the condition, and treating it makes every keratolytic above work at lower irritancy for the same effect.
What's normal: Nothing at this stage should sting at all. An emollient that stings on intact skin is the wrong emollient, and the answer is a different one rather than persistence.
Ready for the next step?
Has the shower routine changed and is an unfragranced emollient going on daily?
Yes — routine changed: The base is in place. Go to step 3 ↓ Go to step 2 ↓
Not yet: This is worth a week on its own before the acid arrives. The step exists to make the next one tolerable, and skipping it is the most common reason the next one gets abandoned.
- Weeks 1–4You are here
One keratolytic, twice daily
Introduce the treatment with the actual evidence behind it, and give it long enough to be judged.
What this step involves
Morning
- Apply the keratolytic to the affected area One product, not two. Ten to twelve per cent lactic acid has the best controlled result in this condition; urea at ten per cent or above is the alternative that treats the dryness at the same time; salicylic acid at two to five per cent is the option that reaches furthest into the follicle. The choice between them is about tolerance rather than potency. Browse all lactic acid products →
Evening
- The keratolytic again, then emollient over the top Twice daily is what the trial used. The emollient goes on afterwards rather than instead — it does not cancel the acid out, and it is what keeps the skin comfortable enough for this to still be happening in March. Browse all moisturizers →
Why this step: This is the step with the numbers attached. In a randomised split-side trial, twice-daily ten per cent lactic acid reduced lesions by about two-thirds over three months and five per cent salicylic acid by about half, with mild local irritation the only adverse effect recorded. Nothing else available without a prescription has a result of that quality in this condition.
What's normal: Mild stinging for the first minute or two, settling over the first fortnight, is expected. Stinging that lasts, spreads or worsens week on week is not tolerance building — it is usually a sign the skin is still being irritated by something else, most often shaving or residual scrubbing.
If it is not tolerated at twice daily
Reducing to once daily is a legitimate plan rather than a compromise. So is applying the emollient first and the acid over it, which blunts the delivery slightly and improves the odds that the product is still in use three months later. A lower percentage used consistently beats a higher one used for a fortnight.
Ready for the next step?
Has one keratolytic been in use for three weeks without escalating irritation?
Yes — it is established: The trial is running properly. Go to step 4 ↓ Go to step 3 ↓
No — it stings or it lapsed: Drop the frequency rather than the plan, and check the shaving and the water temperature before changing product. Most intolerance here is about what else the skin is being subjected to.
- Weeks 4–12You are here
Hold it, and resist the additions
Let the treatment run long enough to be measured, without the extra products that make the result unreadable.
What this step involves
Morning
- The same keratolytic, unchanged Deliberately identical week to week. The trial that produced the two-thirds figure ran three months on one agent, and a routine that acquires a second acid in week six cannot be compared with it or with itself. Browse all lactic acid products →
Evening
- Photograph monthly, same window, same distance Roughness changes slowly enough that daily observation reliably reports nothing. A monthly photograph from a fixed spot is what makes a real improvement visible and what stops a real improvement being abandoned as a failure.
Why this step: Twelve weeks is where the numbers come from. Three weeks is enough to know a product is tolerable and doing something; it is not enough to know how much, and the difference between those two questions accounts for most of the products in most people's bathroom cupboards.
What's normal: A plateau somewhere around week six to eight is normal and is not the ceiling — improvement in the trial continued through the third month.
If only one thing happens this quarter
Keep applying it. Consistency across twelve weeks does more here than any upgrade in strength, and the single most common pattern in this condition is a good product used for a fortnight, judged unsuccessful, and replaced by another good product used for a fortnight.
Ready for the next step?
Has the same routine run unchanged for twelve weeks, with monthly photographs?
Yes — twelve weeks done: That is a complete trial. Go to step 5 ↓ Go to step 4 ↓
Not yet: Hold here rather than adding anything. The checkpoint below is only answerable if the routine it is judging has stayed still.
- Week 12 onwardYou are here
Drop to maintenance, and keep it there
Convert a twelve-week result into a permanent one, which is the step that separates this condition's successes from its relapses.
What this step involves
Morning
- Keratolytic once or twice a week Not stopped. Reduced. Guidance describes weekly or twice-weekly application once adequate improvement has been reached, and that schedule continues indefinitely because the plugs re-form without it. Browse all urea products →
- Emollient stays daily This is the part that does not reduce. It is also the part most easily folded into an existing habit, which is why it tends to survive when the acid does not. Browse all moisturizers →
Evening
- Attach the weekly application to something that already happens A fixed day rather than an intention. The characteristic failure of this condition is not a bad product — it is a good routine that quietly stops over a summer and is restarted in November with the bumps back and the conclusion drawn that the product stopped working.
Why this step: Every published account agrees on two things: nothing here is curative, and the improvement reverses when treatment stops. Maintenance is therefore not the aftercare of the treatment — it is the treatment, in its long-term form, and the only reason it is described as a separate step is that almost nobody is told about it.
What's normal: If the roughness creeps back at once weekly, the answer is twice weekly rather than a stronger product. The dial that matters here is frequency.
A seasonal adjustment is reasonable and expected: many people need twice weekly through the winter and once weekly or less through the summer, which matches the seasonal pattern four in five report.
Ready for the next step?
Is there a specific, written maintenance schedule attached to a day of the week?
Yes — it is scheduled: That completes what is available without a prescription. Go to the checkpoint below ↓ Go to the checkpoint ↓
Not yet: Worth doing now rather than later. An intention to keep it up is the version that fails, and the failure takes six months to become visible.
The twelve-week checkpoint
Twelve weeks counted from the first application of the keratolytic, not from when the routine was first thought about and not from when the emollient started.
How to judge it: Compare photographs from the same window at the same distance, and judge roughness by touch with the back of the hand rather than by colour in a mirror. The two components move at different rates and the colour is the one least likely to have changed, so an overall impression is dominated by the half that was never going to respond.
Twelve weeks of one keratolytic used consistently on a moisturised base — what has the texture done?
Move to maintenance and change nothing else.
This is the expected result and it is the whole aim of the non-prescription tier. The risk from here is not relapse but drift: the improvement makes the routine feel unnecessary, it lapses over a summer, and the condition returns looking like a treatment failure. A weekly application attached to a fixed day is what prevents that, and it is worth more than any upgrade in product.
A reasonable point to ask what else exists.
Partial improvement after a complete twelve-week trial is a good position to bring to an appointment, because it establishes that the approach is right and the question is one of degree. It also makes the choice ahead a genuine one: a prescription retinoid works on the same problem by a different mechanism, and energy-based treatment is the tier with the most consistent published results and the largest bill.
This is the handover point.
Twelve weeks of consistent use with nothing to show for it is exactly the result this checkpoint exists to produce, and it is not evidence of anything done wrong. Two questions are worth raising at that appointment: whether a prescription topical is appropriate, and whether this is the right diagnosis — a stable field of plugs is characteristic, and anything that comes and goes, itches badly or arrived in adulthood deserves a second look.
Stop the acid and go back two steps.
Worse is not a weaker version of no-change and does not call for a stronger product. Skin that is redder and more irritated than it was twelve weeks ago is almost always still being scrubbed, shaved over, or treated with two actives at once. Returning to emollient alone for a fortnight and then reintroducing a single keratolytic at a lower frequency resolves most of it, and a persistent worsening is worth a clinician's eye rather than a change of brand.
What does not wait twelve weeks
Anything that scars does not wait. Pitting, honeycomb marks, or thinning hair in the affected skin describe a different group of variants in which the follicle is being destroyed, and what is lost there does not come back — so those are assessed while the disease is still mild rather than after a course of creams. Eye symptoms alongside them are assessed the same day. Nor does a field of follicular bumps appearing for the first time in adulthood, which is not how this condition ordinarily begins, and which deserves a diagnosis before it gets a treatment.
One photograph a month from the same window at the same distance, plus a note of which product and what frequency. Roughness improves too slowly to register day to day and too quickly to be remembered accurately over a season, and the seasonal swing four in five people report makes month-to-month memory particularly unreliable. Those photographs are also the most useful thing to bring to an appointment, because this condition is entirely legible in a picture and hard to describe in words.
Where the over-the-counter pathway ends
It ends at texture, and it ends without curing anything. Keratolytics measurably reduce the plugs and, used weekly, hold that reduction indefinitely — which is a genuine result and a smaller one than most product marketing implies. What the aisle cannot do is reach the colour: the perifollicular redness answers to vascular devices in a clinic and to essentially nothing on a shelf. What a clinician adds is a topical that corrects the keratinisation rather than dissolving its product, an anti-inflammatory for the days when the colour matters, and access to the device tier that two systematic reviews identify as the most consistently effective treatment there is.
See the prescription pathway below →Keratosis pilaris (chicken skin): the full therapy pathway · dermapproved.com/treatments/keratosis-pilaris/ · not a diagnosis — confirm anything you act on with a clinician
What to expect
The realistic shape is a clear improvement in texture, a smaller one in colour, and no ending. Twelve weeks of a keratolytic reduced lesions by roughly two-thirds in the controlled trial, and that is what a good result looks like — not clearance. The redness is the part that disappoints, and it disappoints predictably: the trial that improved roughness with a laser found erythema statistically unchanged, and the largest series of the red variant reported minimal improvement across every topical tried. On natural history, the widespread belief that this simply goes away with age is only partly true. In the one survey to follow it, about a third improved with age, over two-fifths were unchanged, and around a fifth had worsened, with the mean age of improvement in the mid-teens. Four in five reported a seasonal swing, most often worse in winter. Knowing all of that in advance converts a frustrating condition into a manageable one; discovering it after two years of escalating products does the opposite.
- The trial that produced the numbers ran twelve weeks — abandoning at four is how a working treatment gets recorded as a failure
- Improvement reverses over weeks to months when treatment stops, which is the condition rather than the product failing
- Maintenance at once or twice weekly is the step almost nobody is told about and the one that decides whether a result holds
- Scrubbing harder is the escalation that reliably backfires, and it targets the half that no treatment reaches
- A result judged across two different seasons is measuring the calendar as much as the treatment
Worth going back to a clinician if bumps start leaving pits or marks, if hair thins where they are, if the eyebrows or scalp become involved, if a field of them appears for the first time in adulthood, if the skin has become raw or paler in patches after prolonged treatment, or if any of them become painful or start draining. The ordinary form of this condition is stable and unremarkable, so anything that changes character is worth a second look rather than a stronger product.
What would bring you back sooner
Whatever step you are on, these do not wait for the end of a trial period. They are the same
presentations listed at the top of this page — repeated here because that is where they
matter, rather than where they were easiest to put.
- Pitting, honeycomb scarring, or skin that looks thinned where bumps have been See a dermatologist soon
- Loss of eyebrow hair, eyelashes, or patchy thinning of the scalp See a dermatologist soon
- Light sensitivity, gritty or painful eyes, or a change in vision alongside the skin condition Seek care quickly
- A field of follicular bumps appearing for the first time in adulthood Worth a clinician visit
- Bumps that have become painful, hot, or are draining See a dermatologist soon
- Skin that has become raw, weeping, or paler in patches after prolonged treatment Worth a clinician visit
Prescription only — from here on, this is a clinician's decision The prescription pathway
Why this tier exists. Three limits, and the second is the one nobody says out loud. Nothing here is a cure — UK primary-care guidance states that plainly, and a review of the light and laser literature concluded the condition still lacks any effective long-term treatment. Second, the redness is largely untouched by the entire non-prescription tier: keratolytics work on the plug, and the ring of colour around the follicle is a separate problem that answers to different equipment. Third, everything here is maintenance. Stopping returns the skin to baseline over weeks to months, which is not a treatment failure but is the reason a three-week course produces a three-week result.
Three questions sort this: whether the roughness or the colour is the real complaint, whether it itches, and whether anything is being permanently lost. Read across the top for the presentation and down the side for how far past the aisle each one goes — and note that two of the four columns run out of ladder early, which is the honest shape of this condition.
The same pathway in full below — each step names what it involves, why it sits where it does, and what tells you it's time to move up. Tap any therapy to jump to its detail.
Roughness on the arms, thighs or buttocks
The ordinary presentation and by far the commonest: a permanent field of firm plugs where the complaint is how the skin feels and photographs rather than what colour it is. This is the column with the most to offer, because roughness is the half that measurably responds.
You reach this column when: Twelve weeks of consistent use has produced no change in texture, the keratolytic cannot be tolerated at any frequency, or the result is real but so far short of what was wanted that the device tier is worth costing.
- Prescription topical
A prescription topical
Why this step sits here: The step up is a change of mechanism rather than of strength. A retinoid acts on the faulty keratinisation itself instead of dissolving what it produces, which is a better answer in principle and a harder one to keep using across an area this large.
Two prescription topicals, chosen by which half of the problem is being aimed at rather than by strength:
- A topical retinoid backed by smaller studies
Texture is the complaint and a keratolytic has been tolerated but has not gone far enough. This is the agent whose randomised result covered roughness, redness and itch together, which no other topical here can claim.
- Topical tacrolimus limited evidence
Inflammation around the follicles is a visible part of the picture, or a retinoid has already proved too irritating on skin that is dry to begin with. It also suits a situation where a corticosteroid has been used repeatedly and needs to stop.
When to move up
- A fair trial
- Three months, with frequency built up gradually rather than started daily — the first fortnight is where most of the abandonment happens.
- Improvement looks like
- Fewer palpable plugs and a smoother surface, developing over months rather than weeks.
- Move up if
- Three months of a tolerated retinoid has not changed the texture, or the irritation makes consistent use across the affected area unrealistic.
→ The next step up this pathway.
-
- In-office procedure
Energy-based treatment for texture
Why this step sits here:
Several devices have controlled evidence in this condition, and they are chosen on skin tone, downtime and what is locally available:
- 1064 nm Nd:YAG backed by smaller studies
The device named specifically in both recent systematic reviews, with a sham-controlled trial showing instrument-measured roughness falling over four sessions. Its longer wavelength suits richer skin tones, which is the main reason it is reached for first.
- Fractional CO2 backed by smaller studies
Ablative, with split-body randomised evidence against a topical comparator, and the option that produces the largest textural change per session. It also produces the most downtime and the highest pigment risk, which is the trade being made.
- 810 nm diode backed by smaller studies
A split-body placebo-controlled trial showed roughness improving over three sessions while redness did not. That profile suits someone whose complaint is purely textural, and it is the trial that established the split between the two halves most clearly.
Three questions decide this and none of them is about which laser is newest. What does a full course cost, given that the published protocols treated one arm and most people have four affected areas. How experienced is the practitioner with this specific skin tone, since pigment change is the complication that outlasts the benefit. And what happens afterwards — no device here has demonstrated durability beyond months, so this is a course that improves a baseline rather than one that ends the condition, and the keratolytic underneath it does not stop.
-
The part that decides whether any of it lasts
Whatever produced the improvement, the plugs return over weeks to months once treatment stops, and that is the condition behaving normally rather than the treatment having failed. What holds a result is a keratolytic once or twice a week, permanently, on skin that is being moisturised anyway — a schedule light enough that most people can keep it up and specific enough that it is worth writing down. The commonest pattern after a good twelve weeks is a gradual drift back to nothing over the following summer, followed by a puzzled restart in November. Booking the maintenance into an existing habit, rather than treating it as a course that finished, is the difference.
Redness the main complaint (keratosis pilaris rubra)
Marked colour with follicular prominence in it, most often on the outer cheeks and the upper arms and legs, typically starting in early childhood. It is a recognised variant rather than a severe version of the ordinary one, and it is the presentation where published treatment results are consistently poorest — which is the first thing worth knowing rather than the last.
You reach this column when: The colour is the thing that matters and it is unchanged, or the skin has become more inflamed rather than less on treatment.
- Prescription topical
Prescription topicals aimed at the inflammation
Why this step sits here: This rung is about the ring of colour rather than the plug, which changes the drug class entirely. A corticosteroid is deliberately bounded to a few days at a time, and the non-steroidal option exists precisely because this condition needs treating for years rather than weeks.
Three approaches to the same target, and the difference between them is mostly about how long each can be used:
- A short corticosteroid course limited evidence
The redness needs reducing for a defined event or a short period. Guidance describes a few days at a time and warns explicitly against regular use, so this is a tool for an occasion rather than a plan.
- Topical tacrolimus limited evidence
Anti-inflammatory treatment is needed on an ongoing basis, which is where a corticosteroid cannot go. It is also the option most often reached for on facial skin, where thinning is the limiting concern.
- A topical retinoid backed by smaller studies
The randomised trial in this condition reported redness improving alongside roughness and itch, which makes it the one topical with a controlled result covering colour. Irritation on already-red skin is the obvious tension, and it is introduced slowly for that reason.
When to move up
- A fair trial
- Eight to twelve weeks for the non-steroidal options; a corticosteroid is judged within days because it is not continued beyond them.
- Improvement looks like
- Less background colour between the follicles, and a face or limb that flushes less readily.
- Move up if
- Colour persists after an adequate topical trial, or the only thing that helps is a corticosteroid that cannot be continued safely.
→ The next step up this pathway.
-
- In-office procedure
Vascular laser and light
Why this step sits here:
The device is matched to what is visible and to the skin tone being treated:
- Pulsed dye laser limited evidence
The most reported device for this variant, with case series describing marked reduction in erythema across two to eight sessions. It bruises at the settings that clear vessels fastest, which is a scheduling consideration rather than a complication.
- Intense pulsed light backed by smaller studies
Broader wavelengths over a wider field, which suits diffuse colour spread across a cheek or a whole upper arm. It is also the modality here with a sham-controlled trial behind it, albeit one measuring roughness rather than colour.
- 532 nm KTP limited evidence
Precise on discrete visible vessels rather than on a diffuse field, and reported in this variant in single cases. Its shorter wavelength makes skin tone a more significant consideration than with the alternatives.
This is the only tier that reaches the colour, and the evidence for it is honestly described as small series rather than trials — a systematic review of every light and laser study across all variants of this condition found 175 patients in total. The results reported in those series are good and the confidence attached to them should be moderate. Two practical points carry more weight than the choice of device: pigment change after treatment has been reported in this condition specifically, and a course of several sessions is almost always paid for privately because the classification is cosmetic.
-
Living with the half that does not fully answer
This variant is described as running from early childhood, without the atrophy or scarring of the harder forms, and often improving in adolescence and beyond. That trajectory is worth holding onto, because the treatments available in the meantime are modest and the temptation to keep escalating is strong. What is genuinely worth maintaining is short: the emollient, a mild keratolytic for the plugs, no mechanical exfoliation at all, and a corticosteroid kept firmly in the occasional-use box it belongs in. Where a laser course has helped, the reported durability is months, so this becomes a periodic expense rather than a completed treatment — a fact better costed at the start than discovered at the end.
Itchy, dry, or alongside eczema
The presentation where this stops being a cosmetic question. Itch, tightness and rough dry skin over a wide area, frequently in someone who also has eczema or a strong family history of it — the two share a barrier defect and are found together far more often than chance would explain.
You reach this column when: The itch persists despite generous emollient use, the skin is inflamed rather than merely rough, or there are patches that look more like eczema than like plugged follicles.
- Prescription topical
Treating the inflammation, not the plug
Why this step sits here: Where itch is the dominant symptom, the target is the inflammation rather than the keratin, and a short corticosteroid course settles it faster than any keratolytic. What follows the course matters more than the course: guidance is explicit that regular corticosteroid use on this condition risks thinning the skin, so the plan has to say what happens on day five.
When to move up
- A fair trial
- A defined short course for the corticosteroid, or eight to twelve weeks for a non-steroidal alternative used continuously.
- Improvement looks like
- Itch settling within days on a corticosteroid and over weeks on the alternatives, with the roughness largely unchanged either way.
- Move up if
- The itch returns each time treatment stops, the area needing treatment keeps enlarging, or the picture looks increasingly like eczema rather than this condition.
→ The next step up this pathway.
- Prescription topical
A retinoid, and a look at what sits underneath
Why this step sits here:
The retinoid is the treatment; the accompanying assessment is not a treatment and is listed separately for that reason:
- A topical retinoid for itch and roughness together backed by smaller studies
Itch has persisted through emollients and an adequate anti-inflammatory trial. This is the only agent here with a randomised result covering pruritus specifically, and it is introduced at low frequency and built up.
- Assessment for an underlying association limited evidence
Disease is unusually widespread, unusually severe, or has changed markedly over months. It is a question a clinician answers by history and examination rather than by a fixed panel of tests, and a normal result is a useful outcome rather than a wasted appointment.
Two things happen at this rung. The first is a topical retinoid, which is the only agent in this condition with a randomised result showing itch improving as well as roughness — introduced slowly, because irritating already-itchy skin is the obvious risk. The second is a question rather than a drug. Widespread, unusually severe or abruptly worsening disease is one of the few situations where a clinician looks beneath the surface: the associations described include very dry skin conditions such as ichthyosis vulgaris, atopic dermatitis, higher body weight, diabetes, and androgen excess. None of that changes the cream. It changes whether the cream is the whole of the answer.
-
Where the emollient outlives everything else
In this group the emollient is not the thing that supports the treatment — over years it is the treatment, and the keratolytic becomes the occasional addition rather than the centrepiece. What that looks like in practice is a large tub bought in a quantity that would embarrass anyone treating a cosmetic problem, applied after every shower to skin still damp, indefinitely. Where eczema is present alongside, the two conditions are managed as one routine rather than two, and the flare plan for the eczema takes precedence whenever they disagree.
The scarring variants (keratosis pilaris atrophicans)
A small group in which the follicle is destroyed rather than merely plugged — leaving pitted or honeycomb scarring on the cheeks, or loss of hair from the eyebrows and scalp. It usually begins in early childhood with scalp involvement appearing in the teenage years, and it is the only presentation on this page where the passage of time takes something that cannot be given back.
You reach this column when: There is any pitting, any thinning of hair in the affected area, involvement of the eyebrows or scalp, or new lesions continuing to appear.
- Prescription topical
Prescription topicals, with modest expectations
Why this step sits here: Topical treatment here aims at the active inflammation destroying the follicle rather than at appearance. The honest framing comes from the largest series: across twenty-one people treated with keratolytics, antibiotics, corticosteroids and retinoids, response was limited. Individual case reports of a retinoid halting progression exist and are the basis on which it is tried.
When to move up
- A fair trial
- Three to six months, judged on whether new lesions are still appearing rather than on how the existing ones look.
- Improvement looks like
- New lesions stopping. That is the realistic goal, and it is a meaningful one when what is being prevented is permanent.
- Move up if
- New scarring or further hair loss continues despite topical treatment.
→ The next step up this pathway.
- Prescription oral
Oral isotretinoin
Why this step sits here:
Reached only here, and offered on a genuinely mixed record. Individual reports describe atrophy halted and hair regrowing; the largest series found that most of those treated did not improve and one worsened. The realistic conversation is therefore about stopping progression rather than restoring anything, at doses below acne doses over months, with monitoring and the full pregnancy-prevention requirements attached. Two adjuncts belong in the same appointment rather than on a later one: an eye examination, since photophobia, corneal deposits and early cataracts have been reported alongside these variants, and — where scarring is established rather than active — a discussion of resurfacing, which addresses the texture that is left behind rather than the process that produced it.
After the process has been stopped
Success in this column looks unlike success anywhere else on the page: no new lesions, and everything already lost still lost. What follows is two separate conversations that are easily conflated. One is surveillance — whether the process is genuinely quiet, which is judged over years and by photographs rather than impressions, and which includes keeping the eye assessment current where it was indicated. The other is what to do about scarring that has stabilised, where resurfacing and, historically, dermabrasion have been used to improve the texture left behind. Neither restores a destroyed follicle, and the hair that has gone does not return.
Keratosis pilaris (chicken skin): the full therapy pathway · dermapproved.com/treatments/keratosis-pilaris/ · not a diagnosis — confirm anything you act on with a clinician
When the rules change
The columns above assume an adult treating a limb with a routine that can simply be adopted. Four situations change that, and in three of them what changes is which rungs are available rather than whether treatment is worth doing.
Pregnant, breastfeeding, or planning to be
The ladders shorten from the top, and the part that carries most of the achievable benefit is untouched. This condition has also been described as arising or worsening during pregnancy, which is worth knowing so that a flare is not read as something having gone wrong.
What can be used
- Emollients and non-soap washes, without qualification
- Topical urea, which is widely used in pregnancy for dry-skin conditions
- Topical lactic and glycolic acid on the body, generally regarded as compatible at these concentrations
- The whole maintenance schedule, which is where the durable benefit sits in any case
What comes off the table
- Topical retinoids, contraindicated as a class
- Oral isotretinoin, which is teratogenic and prescribed only inside a mandatory prevention programme
- Elective laser and light treatment, customarily deferred rather than forbidden — the benefit is cosmetic and will still be available afterwards
Salicylic acid is the one that needs a real conversation rather than a class answer, because this condition is often treated across a large surface area twice daily, which is exactly the situation in which the usual reassurance about low-concentration topical use applies least.
Children and teenagers
This is where the condition most often starts, and mild forms in this age group are common enough to be regarded as a normal variant. That framing is a kindness rather than a dismissal — it means the reasonable default is explanation and an emollient, not a search for a stronger product.
What can be used
- Emollients, generously and routinely, which is the whole of the treatment for most children
- A gentle keratolytic where the roughness genuinely bothers the child rather than the parent
- Reassurance about natural history, which is a legitimate intervention here and often the most useful one
- A clinician's opinion where lesions scar, hair is thinning, or the eyebrows and scalp are involved
What comes off the table
- Escalating exfoliation on a child's skin, which is more easily inflamed and marks more readily
- Regular topical corticosteroid use, which risks thinning skin that will carry the condition for years
- Treating a cosmetic concern that belongs to an adult as though it belonged to the child
The scarring variants typically begin in childhood with scalp involvement appearing in the teenage years, which is the one thing worth actively watching for in this age group rather than waiting to be told about.
Richer skin tones
Two differences matter and they pull in opposite directions. The colour component is under-recognised because erythema reads as a darker or duskier tone rather than as pink, so it is more often missed. And the marks left behind last longer and read browner, which raises the cost of every irritating step on the page.
What can be used
- The whole keratolytic tier, introduced more gradually because post-inflammatory marking is the risk being managed
- Longer-wavelength devices such as the 1064 nm Nd:YAG, which is the option most often chosen for this reason
- A practitioner who treats this skin tone routinely, which predicts the result more reliably than the device does
- Photography in consistent light, since the colour component is genuinely harder to judge by eye here
What comes off the table
- Mechanical exfoliation, which carries a higher marking cost here than anywhere else on the page
- Aggressive ablative resurfacing without a practitioner experienced in the skin tone in front of them
- Reading absence of pinkness as absence of the inflammatory component
Post-inflammatory pigment change was reported after laser treatment in this condition specifically, including withdrawals from one trial for that reason. That is a manageable risk rather than a reason to avoid the tier, and managing it is mostly a question of who is holding the device.
When it is unusually extensive or has changed
Most of this condition is stable, limited and unremarkable. Disease that is very widespread, that has worsened markedly over months, or that has appeared for the first time in adulthood is the exception, and it is the one situation in which what sits underneath is worth a look.
What can be used
- The same topical plan, which does not change on account of any association
- A clinician's assessment, which is done by history and examination rather than by a fixed panel of tests
- A review of medications, since follicular eruptions have been described with certain targeted cancer therapies
- A normal result, which is a genuinely useful outcome rather than a wasted appointment
What comes off the table
- Assuming an association explains it — most extensive disease is simply extensive disease
- Delaying treatment while investigation happens, since the two run in parallel
- Reading the reported associations as a reason for alarm rather than as a reason to mention it
The associations described in the literature include very dry skin conditions such as ichthyosis vulgaris, atopic dermatitis, higher body mass index, diabetes and androgen excess. It appeared in twelve per cent of young people with type 1 diabetes against one and a half per cent of matched controls in one study — a real association, and not one that makes this condition a marker anybody should be screened on.
How an appointment actually happens, what to take to it, and how to keep your skin liveable while a prescription or procedure does its work.
What seeing a dermatologist actually looks like
This is diagnosed by looking, and the diagnosis is usually straightforward — which shifts what the appointment is actually for. In most systems the first conversation is with a family doctor, whose guidance describes this as having no cure and emphasises explanation, emollients containing urea or salicylic acid, and topical corticosteroid only for a few days at a time. Referral tends to follow one of three things: a presentation that scars, a diagnosis that does not fit, or a wish to discuss the device tier, which is generally classed as cosmetic and privately funded. Going in expecting a cure and coming out with a leaflet is the usual disappointment; going in with a specific question about the next tier is what makes the visit worth the trip.
What to bring
- Photographs from the same spot over several months, and from the same month in a previous year if any exist
- The names and stated percentages of everything already applied, and how long each ran
- A note of any mechanical exfoliation and how often, which is easy to forget and frequently relevant
- Whether the roughness, the colour or the itch is the thing that actually matters
- Any family history of the same skin, of eczema, or of very dry skin conditions
- Whether anything has ever scarred or left a mark, with a photograph if so
Questions worth asking
- Is this the ordinary form, or one of the variants that scars?
- Which component is realistically treatable in this case — the texture, the colour, or both?
- Is a prescription topical worth trying, and how would it be judged?
- Is any of this available under public funding, or is the next tier private?
- What does maintenance look like once something has worked?
- Does anything here need checking beyond the skin?
- Is any of this affected by pregnancy, now or later?
Cost and access. The non-prescription tier is inexpensive and, on a condition treated over years across a large surface area, the size of the container matters more than the price per gram. Prescription topicals are modest in cost where they are funded, though a retinoid applied to both arms and both thighs consumes a great deal more than the same product on a face. The device tier is the real expense: it is classed as cosmetic in most systems, is therefore paid for privately, and the published protocols treated a single limb — a full course over every affected area is a substantially larger commitment than the trials describe.
A family doctor can diagnose this and prescribe the topical options described here, and UK primary-care guidance covers it explicitly, including the caution that topical corticosteroids must not be used regularly on it. Asking for a dermatology referral is reasonable where lesions scar or hair is being lost, where the diagnosis is uncertain, or where a field of follicular bumps has appeared for the first time in adulthood. A referral purely for cosmetic laser treatment is generally not funded, which is worth establishing early rather than at the end of a wait.
Finding someone to see
How a clinician is reached varies by country, and for a condition classed as benign the first appointment is almost always with a family doctor rather than a specialist.
- US Find a Dermatologist American Academy of Dermatology Searchable by location, with board certification verified in the listing.
- UK Keratosis pilaris NHS Sets out when it is worth seeing a GP and what NHS treatment does and does not cover.
- Australia Keratosis pilaris healthdirect Australia Government-funded information, including how referral works and when to seek advice.
Only regions with a directory or national health service page that resolved this session are listed here.
Skincare alongside therapy
Supporting care here is unusually load-bearing, because one of its components held its own against a prescription ointment in a blinded comparison. The routine below is not what happens around the treatment on a large area of skin — for a good number of people it is most of the treatment.
Two ideas run through all of it. Water on damp skin beats water on dry skin, so timing matters more than formulation. And friction is the enemy rather than the tool: every step here is designed to leave the perifollicular skin alone, because that is the half no product on this page can fix once it has been inflamed.
The routine underneath every column
This is the part that stays constant through prescriptions, through a laser course, through pregnancy and through the years in between. It is short, it is dull, and its dullness is the reason it survives.
Do
- Shorter, cooler showers, with a non-soap wash used only where it is needed
- Emollient onto skin still damp from the shower, within a few minutes rather than an hour later
- Enough of it that a large tub is a normal purchase rather than an extravagant one
- One keratolytic at a stated percentage, and only one
- A monthly photograph from the same window at the same distance
Avoid
- Dry brushes, exfoliating mitts, loofahs, pumice and gritty body polishes
- Very hot water and long soaks, which strip faster than any emollient replaces
- Fragranced body lotion, which keeps the skin quietly reactive without ever being dramatic
- Two acids on the same skin, which makes any reaction unattributable and any result unreadable
What that looks like on a shelf: a gentle cleanser, an emollient for everywhere, a barrier moisturizer.
Where hair removal meets a keratolytic
The legs, the arms and the underarms are frequently both the treated area and the shaved one, and the interaction between those two accounts for a large share of the intolerance blamed on the acid.
Do
- Shave at the end of a shower rather than the start, on softened skin
- Leave at least a day between shaving and the next keratolytic application on the same area
- Use a fresh blade in the direction of growth, which reduces the follicular trauma that mimics a flare
- Apply emollient rather than an acid on the evening of a shave
Avoid
- Exfoliating immediately before shaving, which is a common recommendation elsewhere and a poor one here
- Applying an acid to freshly shaved skin, which is where most of the reported stinging comes from
- Waxing an actively inflamed area, which adds follicular trauma to follicular inflammation
What that looks like on a shelf: an emollient for everywhere.
While a prescription topical is running
The first fortnight of a retinoid on a large body area is where most of the abandonment happens, and almost all of it is about frequency rather than about the drug.
Do
- Build frequency in steps rather than starting at the label maximum on every affected area
- Treat one region first and extend outward once it is settled, rather than starting everywhere at once
- Keep the emollient going underneath or over the top, which does not cancel the treatment out
- Note the stop date for any corticosteroid course at the moment it is started
Avoid
- Running a keratolytic and a retinoid on the same skin on the same day while tolerance is being established
- Continuing a topical corticosteroid past its intended course, which risks thinning the skin it is treating
- Sun exposure on treated areas without cover, since both retinoids and acids increase sensitivity
What that looks like on a shelf: an emollient for everywhere, a barrier moisturizer.
Around a laser or light course
Aftercare here is directed by the clinic performing the treatment. What follows supports that rather than replacing it, and where the two disagree the clinic is right.
Do
- Follow the clinic's aftercare in preference to anything written here
- Protect the treated area from sun while it heals, which is when pigment change is most likely
- Keep to a plain emollient over the treated area, and add nothing else back until the clinic clears it
- Resume the keratolytic only when the clinic says so, and then at a reduced frequency at first
Avoid
- Restarting acids or retinoids before healing is complete
- Any mechanical exfoliation of treated skin, which is how a temporary mark becomes a lasting one
- Booking a course without first costing every affected area rather than the single limb the trials treated
What that looks like on a shelf: an emollient for everywhere.
The supporting shelf
A gentle cleanser
An emollient for everywhere
A barrier moisturizer
The product roles above link to categories rather than to individual products, and for this condition the category genuinely is the decision — what matters is a stated percentage, an unfragranced base, and a container large enough that the quantity the job needs does not feel extravagant. A cheaper product used generously beats a better one used sparingly, and that is not a compromise but the actual finding.
Every therapy named above, in full. Look things up here; it is not meant to be read end to end.
Every therapy, explained
Reference, not reading — every therapy named anywhere above, described the way a clinician would describe it. Nobody reads this section end to end; open the one you were sent here for. Which one is right for you is the appointment's job, not this page's.
Over the counter
Available without a prescription. Each one opens with what to look for on a label, which is the part that stays true regardless of which brand is on the shelf that month.
Over-the-counter Lactic and glycolic acid
Alpha hydroxy acid keratolytics
Generally compatible
Lactic and glycolic acid
Alpha hydroxy acid keratolytics
The best-evidenced thing available without a prescription for this condition, and the topical class the most recent systematic review names first.
At the shelf
A body lotion or cream stating a percentage — around ten to twelve per cent lactic acid, or eight to ten per cent glycolic.
A stated number is the whole point, because these acids are also used at one or two per cent purely as humectants and those products will do nothing to a plug. Ammonium lactate is lactic acid buffered to a gentler pH and appears on labels in place of it. A lotion or cream base beats a serum for an area this size — the arms and thighs together are a large surface, and a product that runs out in a fortnight will not survive as maintenance.
Watch out for: Body scrubs that list an acid somewhere below the abrasive. The grit is doing the opposite of what the acid is for, and rinse-off contact of thirty seconds is not a treatment.
Browse all lactic acid products in our catalog →
How it works
These acids break the ionic bonds holding corneocytes together at the mouth of the follicle, so the plug loosens and sheds rather than accumulating. Lactic acid is also a natural moisturising factor, which means it draws water into the stratum corneum while it works — a dual action that matters on skin that is usually dry underneath.
What the evidence says strong
In a randomised split-side trial of fifty people, twice-daily ten per cent lactic acid reduced lesions by about two-thirds over three months and five per cent salicylic acid by about half, both statistically significant, with improved stratum corneum conductance maintained into follow-up. A 2025 systematic review names lactic and glycolic acids as the preferred topical agents.
Typical course
Twice daily for at least three weeks to know whether it is tolerated and doing anything, twelve weeks before judging the size of the result, then once or twice weekly indefinitely.
Commonly discussed side effects
- Stinging on application, particularly on freshly shaved or recently exfoliated skin
- Mild local irritation, which was the only adverse effect recorded in the controlled trial
- Dryness if used without an emollient alongside it
Worth knowing
- Applied to skin that has just been scrubbed or shaved, the sting is severe enough that most people abandon it — the order of operations matters more than the strength
- Alpha hydroxy acids increase sensitivity to ultraviolet light, which matters for arms and shoulders in summer
- A percentage that is not printed on the box is a percentage that is not worth paying for
Pregnancy: Topical alpha hydroxy acids on the body are generally regarded as compatible with pregnancy and breastfeeding, with negligible systemic absorption at these concentrations. They become proportionally more important then, since the retinoid rungs above are withdrawn.
Why it sits where it does: It leads the non-prescription tier because it has the only head-to-head controlled result in this condition and because it is the agent the current systematic review puts first. It is also the one most likely to be still in use in five years, which for a condition treated by maintenance is the property that decides outcomes.
Over-the-counter Urea creams
Keratolytic humectant
Generally compatible
Urea creams
Keratolytic humectant
One of two topical options named in UK primary-care guidance for this condition, and the one that treats the dryness underneath at the same time.
At the shelf
Ten per cent or higher, stated on the front, in a cream rather than a light lotion.
The percentage decides what the product is. Below about ten per cent urea behaves as a humectant and holds water in the skin; at ten and above it starts breaking down the keratin itself, and the higher strengths sold for heels and elbows are usually too aggressive for the arms. Preparations combining urea with salicylic acid exist and are the traditional compounded approach, pairing an emollient base with the keratolytic in one step.
Watch out for: Urea buried in an ingredient list with no percentage anywhere on the packaging, which is common and which almost always means a humectant-level dose.
Browse all urea products in our catalog →
How it works
Urea disrupts hydrogen bonding in keratin, which softens and loosens the plug, while simultaneously binding water in the stratum corneum. That combination suits this condition specifically, because the skin the plugs form in is usually dry and a purely exfoliating approach leaves it drier.
What the evidence says promising
Named in UK primary-care guidance alongside salicylic acid as an acceptable topical option, and used as the active comparator in a split-body laser trial rather than as a placebo — which is a fair indication of how it is regarded. The direct trial evidence for urea alone in this condition is thinner than for lactic acid.
Typical course
Twice daily initially, then dropped to once or twice a week once the roughness has settled. Many people end up using it as their ordinary body moisturiser and never formally stop.
Commonly discussed side effects
- Stinging on broken or shaved skin, which is more pronounced at the higher percentages
- A faintly ammoniac smell in some preparations
- Temporary redness after application on already-inflamed skin
Worth knowing
- High-strength preparations sold for callused heels are not intended for the arms and are a common cause of an avoidable reaction
- Combining it with a second acid on the same skin is how tolerance problems start; one keratolytic at a time is the rule
- It is not a substitute for an emollient on very dry skin so much as a version of one that also works
Pregnancy: Topical urea is considered compatible with pregnancy and breastfeeding and is widely used in that setting for dry-skin conditions. Nothing about this condition changes that assessment.
Why it sits where it does: It shares the first rung with the alpha hydroxy acids rather than sitting below them, because the choice between the two is about skin dryness and tolerance rather than potency. Where the skin underneath is very dry, this is frequently the one that gets used consistently, and consistency is what this condition is decided by.
Over-the-counter Salicylic acid
Beta hydroxy acid keratolytic
Individualized — ask a clinician
Salicylic acid
Beta hydroxy acid keratolytic
The other agent named in UK primary-care guidance, and the one whose oil solubility suits a condition that lives inside the follicle.
At the shelf
Two to six per cent in a leave-on lotion or cream for the body.
Being oil-soluble, it penetrates the follicle rather than working only across the surface, which is the specific argument for it in a follicular condition. Two per cent is the everyday strength; the trial that produced the numbers used five. Preparations compounding it into a urea base exist and are the traditional approach for widespread disease, combining the keratolytic with something that treats the dryness around it.
Watch out for: Medicated body washes built on salicylic acid. Contact time is measured in seconds in a shower, and this needs to be left on to do anything.
Browse all salicylic acid products in our catalog →
How it works
It dissolves the intercellular cement between corneocytes and, unlike the water-soluble acids, partitions into the sebum-rich follicular canal where the plug actually sits. That is a mechanistic argument rather than a demonstrated advantage — in the one head-to-head trial it came second.
What the evidence says strong
In the randomised split-side trial, five per cent salicylic acid twice daily reduced lesion counts by about half over three months — statistically significant, and behind ten per cent lactic acid over the same period. It is one of two topicals named in current UK primary-care guidance.
Typical course
Twice daily for the first three weeks, reviewed at twelve, then reduced to a weekly or twice-weekly application held indefinitely.
Commonly discussed side effects
- Dryness and fine flaking, particularly in winter
- Stinging where the skin is already irritated
- Redness on skin that has been scrubbed
Worth knowing
- Applying it over a very large body-surface area repeatedly is the one situation where systemic absorption is worth a thought, and it is worth raising with a pharmacist where the area is extensive
- Not combined with another acid on the same skin
- Avoided on skin that is currently raw from mechanical exfoliation, which is the commonest reason it seems intolerable
Pregnancy: Low-concentration topical salicylic acid on limited areas is generally regarded as acceptable in pregnancy, but this condition often involves a large surface area applied twice daily, which is the situation where the usual reassurance is least applicable. Worth confirming with whoever is providing antenatal care rather than assuming from the class.
Why it sits where it does: It sits alongside the other keratolytics rather than above or below them. The mechanistic case for reaching into the follicle is good and the head-to-head result put it second, so it is presented as an equal option chosen on tolerance rather than as a step up.
Over-the-counter Plain emollients and the bathing routine
Barrier support
Generally compatible
Plain emollients and the bathing routine
Barrier support
The layer everything else is applied over, and — on the evidence — a more active participant than it is usually given credit for.
At the shelf
An unfragranced ointment or thick cream, and a non-soap wash to replace whatever is currently being used.
The thing worth knowing about this category is that it outperformed expectations in the one trial that tested it properly: a plain petrolatum-based ointment was compared against a prescription anti-inflammatory and the two were not significantly different. Applied to skin still damp from the shower it holds considerably more water than applied to dry skin. Quantity matters more than formulation on an area this size.
Watch out for: Body washes marketed for this condition on the strength of a token acid. The wash is the part of the routine that should be doing the least.
Browse all petrolatum products in our catalog →
How it works
Reducing water loss through the barrier softens the stratum corneum, which makes the plugs easier to shed and makes every keratolytic above work at a lower effective irritancy. In skin carrying a barrier defect, which a substantial share of this population does, that is treating the substrate rather than comforting it.
What the evidence says promising
In a double-blind comparative trial of twenty-seven people, a petrolatum-based ointment and prescription tacrolimus ointment both improved the condition and were both well tolerated, with the difference between them not reaching statistical significance. Emollient use is standard in every published description of management.
Typical course
Daily, permanently, and independently of whatever else is running. This is the rung that never stops.
Commonly discussed side effects
- Heavier ointments are greasy enough that they are usually confined to night-time use on the limbs
- Occlusive products on the trunk can provoke folliculitis in a minority
Worth knowing
- Applied to dry skin an hour after a shower it does a fraction of the job it does on damp skin
- Fragranced body lotions are the most common avoidable irritant in this routine
- Very hot showers and long soaks strip the barrier faster than any emollient replaces it
Pregnancy: Emollients and non-soap washes are compatible with pregnancy and breastfeeding without qualification, and this rung carries more of the load then because the retinoid options above are withdrawn.
Why it sits where it does: It sits on the foundation rung rather than in supporting care because of the trial above. A category that holds its own against a prescription ointment in a blinded comparison has earned a place in the treatment list, whatever its reputation as a comfort measure.
Over-the-counter Gentle mechanical exfoliation, and where it stops
Physical exfoliation
Generally compatible
Gentle mechanical exfoliation, and where it stops
Physical exfoliation
The step nearly everyone tries first, included here because its limits are the most useful thing on this page rather than because of what it achieves.
At the shelf
A soft synthetic sponge or cloth, if anything at all. Not a brush, not a pumice, not a sugar or salt scrub.
The published support for this is a single 1984 report in which a polyester sponge was used to apply a compounded keratolytic, and the mechanical element there was a delivery method rather than the treatment. Used lightly, once or twice a week, on skin that is not already irritated, a soft sponge is defensible. Used daily with pressure, it is the single most reliable way to make this condition look worse than it did before treatment started.
Watch out for: Dry brushes, exfoliating gloves, gritty body polishes and anything marketed as buffing the bumps away. The plug is inside the follicle and cannot be abraded off the top of it.
How it works
Friction removes surface corneocytes, which briefly smooths the skin and does very little to a plug seated inside the follicular canal. What it reliably does reach is the perifollicular skin, where mechanical irritation adds inflammation to the exact component of this condition that no treatment on the page removes.
What the evidence says limited
One report from 1984 describes a polyester sponge used to apply a compounded salicylic-acid-in-urea preparation to widespread disease, with clearance in most patients over two to three weeks. Current UK primary-care guidance mentions exfoliation with a buff as something patients may wish to try, alongside an explicit statement that no cure exists.
Typical course
At most once or twice a week, briefly and without pressure, and stopped entirely at the first sign of soreness.
Commonly discussed side effects
- Perifollicular redness that outlasts the smoothing by days
- Post-inflammatory marks, which last longer and read browner on richer skin tones
- A cycle in which the roughness returns faster after each session, prompting more frequent scrubbing
Worth knowing
- Escalating the abrasion is the characteristic mistake in this condition, and it targets the half that does not respond
- Never on the same day as a keratolytic, and never before shaving
- If the skin is pink for more than an hour afterwards, the method was too aggressive regardless of how it felt at the time
Pregnancy: Physical exfoliation raises no pregnancy considerations. The caution about pressure and frequency is unchanged, and applies for the same reasons it always does.
Why it sits where it does: It appears on the foundation rung as a bounded option rather than being left off the page. Omitting it would not stop anyone doing it — it is the default instinct for a rough texture — and stating its ceiling plainly is more use than pretending the category does not exist.
Browse the whole catalog for this condition:
What changed recently: Nothing new has arrived on the shelf, and the change is in what the evidence says about what is already there. Two systematic reviews published since 2020 have reordered the field: both conclude that energy-based devices produce the most consistent results, and one names lactic and glycolic acids as the topicals of choice while describing the overall strategy as multimodal and centred on explaining the condition rather than on any single product. That last phrase is the most useful thing published about this condition in a decade, and it is not a product recommendation.
Prescriptions and procedures
About the brand names below. Brand names are what the pharmacy label says; the generic name underneath is what actually matters, and it is the part that stays true when a brand is discontinued or a region carries a different one. Where a region is missing from a card below, that reflects what could be verified rather than proof of absence.
Where prescription cards below carry a label link, it points at a national medicines source rather than at a manufacturer. Every prescription treatment described on this page is used outside its licensed indication for this condition, so the leaflet will describe acne, psoriasis or eczema instead — which is routine and lawful, and means the document will not mention these bumps at all.
Prescription topical Topical retinoids
Prescription topical retinoids
Avoid in pregnancy
Topical retinoids
Prescription topical retinoids
The prescription topical with a randomised trial behind it in this condition, and the only agent shown to improve all three of roughness, redness and itch together.
What it's called at the pharmacy
Generic name Topical retinoids
Sold as
- Tretinoin and adapalene preparations are prescribed for this off-label; tazarotene cream is not routinely stocked
A region missing here reflects what could be verified this session rather than what is available.
How it works
Retinoids normalise the keratinisation of the follicular lining — the process that is going wrong here — rather than dissolving the plug after it has formed. That is a mechanistically better answer than a keratolytic and a considerably harder one to tolerate, and the difficulty is why it sits above rather than beside the acids.
What the evidence says promising
A randomised, placebo-controlled, double-blind study of thirty-three people using tazarotene 0.05% cream on the arms reported statistically significant improvement in itch, redness and roughness. That trial was published as a conference abstract rather than a full paper, which is a real limitation on how much weight it carries.
- Tazarotene 0.05% cream for the treatment of keratosis pilaris
- Treatment of keratosis pilaris and its variants: a systematic review
Typical course
Introduced at a low frequency and built up over weeks, with three months a fair assessment period. Irritation in the first fortnight is the usual reason it is abandoned.
Commonly discussed side effects
- Dryness, peeling and redness, particularly in the first month
- Increased sensitivity to sunlight on areas that are frequently uncovered
- A transient worsening in appearance before improvement
Worth knowing
- Contraindicated in pregnancy as a class
- The area involved is often large, and applying a retinoid across both arms and both thighs is a considerably bigger undertaking than treating a face
- Building up frequency slowly is what determines whether it is still in use at three months
Pregnancy: Topical retinoids are avoided in pregnancy and when trying to conceive, and tazarotene in particular carries a specific contraindication. Where treatment is wanted during pregnancy, the ladder restarts at the keratolytic tier, which is where most of the achievable benefit sits in any case.
Why it sits where it does: It occupies the first prescription rung because it addresses the fault rather than its product, and because it is the only topical here with a randomised result covering the colour component as well as the texture. It sits above the acids rather than beside them purely on tolerability.
Prescription topical Topical tacrolimus
Non-steroidal anti-inflammatory topical
Individualized — ask a clinician
Topical tacrolimus
Non-steroidal anti-inflammatory topical
A non-steroidal anti-inflammatory ointment borrowed from eczema practice, used here where the inflammatory ring around the follicle is the complaint and where a corticosteroid cannot be continued.
What it's called at the pharmacy
Generic name Topical tacrolimus
Sold as
- Protopic — tacrolimus ointment 0.03% and 0.1%
A region missing here reflects what could be verified this session rather than what is available.
How it works
It blocks calcineurin in T cells and so suppresses the local inflammatory signalling, without the skin thinning that limits how long a corticosteroid can be used on the same area. In a condition treated over years on a large surface, that difference is the entire reason the class is considered.
What the evidence says limited
A double-blind comparative trial of twenty-seven people found tacrolimus 0.1% ointment more likely than a plain petrolatum-based ointment to produce major improvement, but the difference did not reach statistical significance and both arms improved. A systematic review lists it among the topicals with supporting evidence.
Typical course
Twice daily, reviewed at eight to twelve weeks, and generally used on a limited area rather than across every affected surface.
Commonly discussed side effects
- Burning and stinging in the first few days of use, which is the commonest reason it is stopped
- Warmth and flushing on application, more noticeable with alcohol
- Sensitivity to sunlight on treated areas
Worth knowing
- Used outside its licensed indication here, so the leaflet will describe eczema
- The class carries a boxed warning in some countries based on theoretical long-term risk, which a prescriber will discuss
- Cost becomes the practical constraint when the area involved is both arms and both thighs
Pregnancy: Systemic absorption from intact skin is low, but human pregnancy data are limited and the surface areas involved in this condition can be large. Whether it is used is a prescriber's judgement made alongside antenatal care rather than a class rule.
Why it sits where it does: It shares the first prescription rung with the retinoids rather than sitting above them, because the two are chosen for different halves of the problem — one for the plug, one for the inflammation around it — and no trial has compared them.
Prescription topical Short-course topical corticosteroid
Topical corticosteroid, time-limited
Individualized — ask a clinician
Short-course topical corticosteroid
Topical corticosteroid, time-limited
A few days of an anti-inflammatory cream to take the colour down, used deliberately as a short intervention and explicitly not as ongoing treatment.
What it's called at the pharmacy
Generic name Short-course topical corticosteroid
Sold as
- Clobetasone butyrate 0.05% cream is the example named in primary-care guidance for a few days' use before an occasion
A region missing here reflects what could be verified this session rather than what is available.
How it works
Corticosteroids suppress the perifollicular inflammation that produces the redness, which is why they work quickly on the colour and do nothing at all to the plug. The same suppression, continued, thins the skin — and thinned skin around a follicular condition is a worse starting point than the one being treated.
What the evidence says limited
Described in current UK primary-care guidance as an option for a few days at a time where perifollicular redness is significant, with an explicit warning against regular use because of skin atrophy. In published series of the harder variants, corticosteroids were among the treatments producing limited response.
Typical course
A few days at a time, then stopped, with treatment returning to keratolytics once the inflammation has settled. It is not a maintenance option and is not intended to become one.
Commonly discussed side effects
- Skin thinning with repeated or prolonged use, which is the limiting problem rather than a remote risk
- Stretch marks where the skin is under tension, particularly on the upper arms and thighs
- Rebound redness when a longer course is stopped abruptly
Worth knowing
- Regular use on this condition is specifically advised against in primary-care guidance
- Potency and duration on the face differ from the limbs and are a prescriber's decision
- Its rapid effect on colour makes it the easiest treatment here to overuse, which is precisely why the duration is stated before the benefit
Pregnancy: Short courses of low- to mid-potency topical corticosteroid over limited areas are commonly regarded as acceptable in pregnancy, with potency and quantity the factors that matter. Anything beyond a brief course belongs with whoever is providing antenatal care.
Why it sits where it does: It sits on the prescription tier as a bounded tool rather than as a rung anyone climbs to permanently. Its honest description is a treatment for a fortnight in someone's life rather than a treatment for the condition.
Procedure Resurfacing and non-ablative lasers
Energy-based devices for texture
Individualized — ask a clinician
Resurfacing and non-ablative lasers
Energy-based devices for texture
The tier with the most consistent published results in this condition, aimed squarely at the roughness rather than the colour.
How it works
These devices work by controlled thermal injury to the follicle and surrounding dermis, prompting remodelling of the tissue that is producing the plug rather than removing the plug itself. That is a different proposition from anything topical, and it is why results persist for months rather than days after treatment stops.
What the evidence says promising
Several sham-controlled and split-body randomised trials support this tier: a 1064 nm Nd:YAG laser significantly reduced instrument-measured roughness over four sessions against sham irradiation, and an 810 nm diode laser improved roughness in a split-body placebo-controlled trial. Two systematic reviews conclude that energy-based treatment is the most consistently effective modality, with the Nd:YAG named specifically.
Typical course
Three to four sessions at roughly four-week intervals in the published trials, with assessment several weeks after the last. Durability beyond a few months is not established for any device.
Commonly discussed side effects
- Post-inflammatory pigment change, which caused two withdrawals in the diode laser trial
- Transient redness and swelling for days after each session
- Discomfort during treatment over a large area
Worth knowing
- Pigment change is the risk that matters, and it is higher on richer skin tones — practitioner experience with the specific skin tone predicts the result more reliably than the device does
- Almost always paid for privately, since this is classed as cosmetic in most systems
- The trials treated a single arm; treating every affected area is a substantially larger commitment than the published protocols describe
Pregnancy: Elective energy-based treatment is usually deferred during pregnancy — not because harm has been shown, but because there is nothing to gain by accepting an unquantified risk for a cosmetic benefit that will still be available afterwards.
Why it sits where it does: It sits at the top of the texture column because two systematic reviews put it there, and because it is the only tier that produces a result which outlasts the treatment by months. It sits at the top rather than earlier because it is expensive, uncomfortable and not curative.
Procedure Vascular laser and light
Energy-based devices for erythema
Individualized — ask a clinician
Vascular laser and light
Energy-based devices for erythema
The only tier on this page that reliably addresses the redness, and the reason the colour-led column exists separately from the texture-led one.
How it works
Pulsed dye, potassium titanyl phosphate and broad-spectrum intense pulsed light are absorbed preferentially by haemoglobin, which lets them target the dilated perifollicular vessels producing the colour while leaving the surrounding skin largely alone. Nothing applied to the skin does this, which is why the redness sits outside the reach of the entire topical tier.
What the evidence says limited
The published experience is small series and case reports rather than randomised trials — a systematic review of light and laser treatment across all variants of this condition found seventeen studies covering 175 patients in total. Reported outcomes for erythema are consistently good and the evidence supporting them is thin; intense pulsed light has one sham-controlled trial behind it.
Typical course
Two to eight sessions in the reported series, spaced several weeks apart, with reported durability of months rather than years.
Commonly discussed side effects
- Bruising after pulsed dye laser at the settings that clear vessels fastest
- Post-inflammatory hyperpigmentation, reported after treatment in this condition
- Temporary swelling and redness for several days
Worth knowing
- The evidence here is weaker than for the texture-directed devices, and expectations should be set from the case series rather than from the marketing
- Facial treatment on a young person is a different conversation from treating an arm, and is usually a specialist one
- Cosmetic classification means this is rarely funded
Pregnancy: As with the resurfacing devices, elective vascular laser is customarily postponed during pregnancy on the grounds that the benefit is cosmetic and can wait, rather than because a specific harm has been demonstrated.
Why it sits where it does: It sits at the top of the colour column and nowhere else. Vascular devices do nothing for the plugs, and putting them on the texture ladder would offer an expensive answer to a question they do not address.
Prescription oral Oral isotretinoin
Systemic retinoid
Avoid in pregnancy
Oral isotretinoin
Systemic retinoid
Reserved entirely for the scarring variants, where the goal is halting progression rather than improving appearance — and where even that is inconsistent.
What it's called at the pharmacy
Generic name Oral isotretinoin
Sold as
- Initiated by a consultant dermatologist, with the pregnancy-prevention programme applying in full whatever the dose
A region missing here reflects what could be verified this session rather than what is available.
How it works
Isotretinoin alters follicular keratinisation and shrinks sebaceous glands, and it is the systemic agent with the broadest effect on follicular disease. Why it helps some scarring variants and not others is not explained, and the published record reflects that unpredictability rather than resolving it.
What the evidence says limited
The record is case reports pointing in both directions. Individual reports describe progression of atrophy halted and hair regrowth in the scarring variants; a series of twenty-one people with keratosis pilaris atrophicans found response to keratolytics, antibiotics, corticosteroids and retinoids alike to be limited, and among those given isotretinoin most did not improve.
Typical course
Months rather than weeks in the published reports, at doses below those used for severe acne, with the endpoint defined as no new lesions rather than clearance of existing ones.
Commonly discussed side effects
- Dryness of lips, eyes and nasal lining, which is close to universal
- Muscle aches and occasional disturbance of night vision
- Changes in blood lipids and liver enzymes, which is what the monitoring covers
- Mood changes, discussed at every consultation as part of the standard process
Monitoring
Blood tests before and periodically during treatment, together with the pregnancy testing and contraception requirements applying to everyone who can become pregnant.
Worth knowing
- Cannot be taken during pregnancy at any dose, and the prevention programme runs alongside every prescription
- It has no role in the ordinary form of this condition, where the risk-to-benefit calculation is not close
- Reported results in the scarring variants are inconsistent, and one series described worsening in a treated patient
Pregnancy: The birth defects isotretinoin causes are severe and well characterised, which is why prescribing sits inside a mandatory programme of testing and contraception spanning the period before, throughout and after a course. Nothing about a low dose or a cosmetic indication relaxes any of that.
Why it sits where it does: It appears only at the top of the scarring column, because that is the only place the risk is arguable. On a cosmetic condition affecting the backs of the arms it would be an indefensible trade, and saying so is more useful than listing it as an option.
On the horizon
Pipeline information current as of 2026-09-01
Only treatments in phase 3 trials, submitted to a regulator, or recently approved for this indication. Earlier-stage work is excluded because most of it never arrives, and listing it turns a research programme into an expectation.
This changes nothing about what to do now. Nothing in this section changes what is available or advisable today. It is here so that a reader knows what is moving, not so that anyone defers treatment waiting for it.
In late-stage development
There is nothing to list, and the reason is structural rather than a gap in the search. This condition is benign, common and classed as cosmetic, which means it attracts almost no commercial drug development — no agent has been taken through a registration programme for it, and none is in one now. Movement is happening in two places instead. Genetics is the more interesting: the association with filaggrin variants and with the barrier defect underlying eczema is being mapped in cross-sectional studies, and understanding why the follicle plugs is a precondition for anything better than dissolving what it produces. The other is device protocols, where sham-controlled trials of laser and light have appeared over the last several years and are the only part of this field where controlled evidence is accumulating at all.
The other things people try
This condition attracts an unusually large field of half-treatments, because it is visible, permanent and has no cure — which is exactly the combination the wellness market is built for. What follows is where the popular options actually stand.
- Dry brushing and exfoliating mitts limited evidence
The most widely recommended approach and the one with the clearest case against it. No controlled evidence supports it, the single published report involving a sponge used it to apply a keratolytic rather than as a treatment, and the mechanism runs the wrong way — friction cannot reach a plug inside a follicle but it can readily inflame the skin around one. Current primary-care guidance mentions a buff as something people may wish to try, in the same breath as stating that no cure exists.
- Ammonia-oxidising bacteria sprays backed by smaller studies
Genuinely more interesting than it sounds. A randomised, double-blind, placebo-controlled trial of a live Nitrosomonas eutropha spray reported complete clearance in nine of twenty-four treated participants against three of twenty-four controls after four weeks. That is a real result from a real trial design, on a small sample, never replicated, and the commercial products in this category vary considerably from what was tested.
- Chlorine dioxide complex cleansers limited evidence
A case series described rapid improvement with a cleanser combining antimicrobial and keratolytic action. Uncontrolled, small, and published by authors with a stated interest in the product. Worth knowing it exists because the claim is unusually strong; not worth treating as established.
- Photopneumatic therapy limited evidence
An unblinded study of ten people reported improved erythema lasting at least a month after a single treatment. That is a plausible signal on the component nothing else reaches, from a design that cannot separate it from natural variation. Not widely available, and superseded in the literature by the sham-controlled device trials.
- Topical sirolimus for the red variant limited evidence
A case report of a teenager with the red facial variant described near-complete resolution of erythema and burning after two months of a compounded 1% cream, with negligible serum levels at follow-up. One patient, a compounded preparation, and no established monitoring protocol — which is the honest description of something that may turn out to matter and currently does not.
- Coconut oil, apple cider vinegar and kitchen keratolytics limited evidence
Vinegar is dilute acetic acid and coconut oil is an emollient, so neither is absurd in principle. In practice the concentration is unknown, the pH is uncontrolled, and the two products with the same mechanisms and a stated percentage cost very little. The emollient half of this is defensible; the acid half is a worse version of something already on the shelf.
- Dietary elimination and supplements limited evidence
Gluten, dairy and vitamin A deficiency all circulate as explanations. There is no trial of any dietary intervention in this condition, and the inherited barrier basis makes the premise unpromising. The exception worth naming honestly is that it has been described alongside malnutrition — which is a statement about severe deficiency states, not about ordinary diets.
- Waiting for it to go away limited evidence
Included because it is the most frequently given advice and it is only partly right. In the one natural-history survey, about a third improved with age, over two-fifths were unchanged and around a fifth worsened, with a mean age of improvement in the mid-teens. As a reason not to treat someone who is bothered by it, that is a poor basis; as reassurance for a parent of a young child, it is reasonable.
Sources and further reading
The staging, escalation points, and therapy descriptions on this page are anchored to published clinical guidelines rather than editorial judgment.
What this page is built on
- Keratosis pilaris (and its variants) — clinical guidance
- Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment
- Treatment of keratosis pilaris and its variants: a systematic review
The studies behind this pathway
No single guideline stands behind this page, so it rests on primary-care guidance, three systematic reviews and the controlled trials underneath them. Every link below was resolved against the journal record before publication; a citation printed without one could not be confirmed rather than having been left out.
- Epidermal permeability barrier in the treatment of keratosis pilaris The head-to-head lactic acid and salicylic acid figures the whole non-prescription tier rests on.
- Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment The ladder order, the naming of lactic and glycolic acids as preferred topicals, and the framing of management as centred on explanation.
- Treatment of keratosis pilaris and its variants: a systematic review The finding that energy-based treatment is the most consistently supported modality, and the standing of the topical options.
- Light and Laser Treatments for Keratosis Pilaris: A Systematic Review The total size of the device evidence base, and the statement that no effective long-term treatment exists.
- Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial The central claim of this page — roughness improved while baseline erythema did not — and the pigment-change withdrawals.
- Innovative 1064-nm Nd:YAG Laser Significantly Improves Keratosis Pilaris, A Randomized, Double-Blind, Sham-Irradiation-Controlled Trial The sham-controlled evidence for the Nd:YAG at the top of the texture column.
- Intense Pulsed-light Therapy Significantly Improves Keratosis Pilaris: A Randomized, Double-blind, Sham Irradiation-controlled Trial The sham-controlled result for intense pulsed light referenced on the vascular card.
- Fractional Carbon Dioxide Laser for Keratosis Pilaris: A Single-Blind, Randomized, Comparative Study The ablative resurfacing option among the device choices.
- Clinical and dermoscopic evaluation of fractional carbon dioxide laser in management of keratosis pilaris in Egyptian type skin The split-body comparison against topical urea, and evidence in richer skin tones.
- A comparative trial comparing the efficacy of tacrolimus 0.1% ointment with Aquaphor ointment for the treatment of keratosis pilaris Both the tacrolimus card and the argument that a plain emollient belongs in the actives list rather than in supporting care.
- Tazarotene 0.05% cream for the treatment of keratosis pilaris The randomised retinoid result covering itch, redness and roughness. Published as a conference abstract, and no indexed record could be resolved for it.
- Practical management of widespread, atypical keratosis pilaris The compounded salicylic-acid-in-urea approach and the only published use of a sponge in this condition.
- Natural history of keratosis pilaris Every natural-history figure on this page: site distribution, family history, the seasonal swing, and what actually happens with age.
- Keratosis pilaris rubra: a common but underrecognized condition The description of the red variant and the finding that most treatments produced minimal or no improvement in it.
- Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans The scarring column: the age pattern, the scalp involvement, and the limited response across every treatment class.
- Keratosis pilaris atrophicans. One heterogeneous disease or a symptom in different clinical entities? The heterogeneity of the scarring variants and the associated ocular findings.
- Keratosis pilaris and filaggrin loss-of-function mutations in patients with atopic dermatitis - Results of a Finnish cross-sectional study The barrier-defect association underlying the itchy column and the emollient-first sequence.
- The prevalence of cutaneous manifestations in young patients with type 1 diabetes The prevalence figures quoted for the metabolic association.
- Dermal Microflora Restoration With Ammonia-Oxidizing Bacteria Nitrosomonas Eutropha in the Treatment of Keratosis Pilaris: A Randomized Clinical Trial The ammonia-oxidising bacteria entry among the lower-evidence options.
- Chlorine Dioxide Complex Cleanser: A New Agent With Rapid Efficacy for Keratosis Pilaris The chlorine dioxide cleanser entry among the lower-evidence options.
- Photopneumatic therapy for the treatment of keratosis pilaris The photopneumatic therapy entry among the lower-evidence options.
- Keratosis pilaris rubra successfully treated with topical sirolimus: Report of a case and review of the literature The topical sirolimus case report described among the lower-evidence options.
There is no dedicated national guideline for this condition, which is unsurprising for something classed as benign. What exists is primary-care guidance, three systematic reviews published since 2020, and a small number of controlled trials underneath them — that is the honest footing for everything above.
Guidance and evidence reviews
The first is what a UK family doctor is most likely working from; the other two are the current syntheses, and they differ interestingly in emphasis.
- Keratosis pilaris (and its variants) — clinical guidance Primary Care Dermatology Society (UK) Blunt about the ceiling — no cure, treatment rarely helpful — and specific about the corticosteroid caution that matters most.
- Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment European Journal of Dermatology The most recent synthesis, naming lactic and glycolic acids as the preferred topicals and proposing a stepwise approach centred on explanation.
- Light and Laser Treatments for Keratosis Pilaris: A Systematic Review Dermatologic Surgery Seventeen studies covering 175 patients in total — useful for calibrating how much confidence the device tier actually carries.
Patient information
Written to be read rather than decoded, and useful for the conversation about what is realistically achievable.
- Keratosis pilaris NHS (UK) Short and clear about what is and is not available through the NHS for this.
- Keratosis pilaris British Association of Dermatologists The patient leaflet, with more detail on the variants than most consumer sources carry.
- Keratosis pilaris DermNet Images across skin tones and a fuller description of the variants, which is where most consumer coverage stops short.
Take the charts with you
Print exactly the piece you need. Each chart is one landscape page — no prose, no controls, sized to pin up or hand to someone — and the full document is the whole pathway as it reads on screen. Every printout carries the date, the source, and a line making clear it is not a diagnosis.
Printing happens in your browser. Your answers stay private — saved on this device, and to your free account when you're signed in.